The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of New Drugs Director instructs FDA reviewers to return to the practice of meeting 90 percent of their review time goals for new drug applications.
You may also be interested in...
GAO Gives FDA Drug Review Performance Seal Of Approval
FDA met most user fee performance goals for NDAs and BLAs received in fiscal years 2000 through 2010, the government watchdog agency says in a report prepared for Sens. Burr and Coburn. The legislators proposed legislation April 16 that includes a requirement for the agency to report annually on its adherence to the user fee goals.
Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says
CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.
Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says
CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.